Simultaneous presentation of breast cancer and malignant phyllodes tumour is rare. A female patient presented with a nodule in her left breast (infiltrating ductal carcinoma). On magnetic nuclear resonance another suspicious lesion (malignant phyllodes) was found in the right breast. Bilateral mastectomy was performed. Thirty two months later the patient is still free of disease. The approach to dealing with synchronous breast tumours should be the same as that normally used.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s12094-006-0140-7 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A Rare Case of Primary Chondrosarcoma of the Breast: A Case Report and Comprehensive Literature Review.
Discoveries (Craiova)
September 2024
Department of Oncopathology, Homi Bhabha Cancer Hospital (HBCH) and Mahamana Pandit Madan Mohan Malviya Cancer Centre (MPMMCC), Tata Memorial Centre, Homi Bhabha National Institute (HBNI), Varanasi, India.
Breast sarcomas are a diverse group of malignant neoplasms originating from the mammary stroma. They are uncommon tumors, often occurring as a component of other tumors. Among malignant breast mesenchymal tumors, pure sarcomas lacking epithelial components are even rarer, comprising only 0.
View Article and Find Full Text PDFBackground: Phyllodes tumors (PTs) are fibroepithelial neoplasms of the breast, with current treatment guidelines recommending wide excision to achieve surgical margins of ≥1 cm to minimize the recurrence risk. However, diagnostic challenges with core biopsy specimens often result in suboptimal surgical margins. This study aims to elucidate the correlation between margin status and PT recurrence, thereby informing surgical decision-making and enhancing patient outcomes.
View Article and Find Full Text PDFPrimary Breast Malignancy in Children and Adolescents: A Population-Based Study.
Breast J
January 2025
Department of Pediatric Intensive Care Unit, Hangzhou Children's Hospital, Hangzhou, Zhejiang, China.
Article Synopsis
- Primary breast cancer in children and adolescents is rare and has distinct characteristics compared to adult cases, necessitating a study to predict survival rates in this population.
- The study analyzed 115 pediatric patients, primarily focusing on demographic data and tumor characteristics, finding significant predictors of overall survival (OS) to be the SEER and M stages of cancer.
- A nomogram was developed to aid in predicting OS, addressing a gap in research by providing comprehensive insights into pediatric breast cancer prognosis.
Proliferative Myositis of the Breast in a Patient with Contralateral Phyllodes Tumor: A Unique Pseudomalignant Lesion.
Ann Ital Chir
December 2024
Department of Pathology, Bakirkoy Dr. Sadi Konuk Education and Research Hospital, 34147 İstanbul, Türkiye.
Article Synopsis
- A case of proliferative myositis (PM) of the breast is presented, marking only the second documented instance in English literature.
- A 49-year-old woman developed a rapidly growing mass in her right breast after surgeries for other tumors, leading to initial concerns about malignancy; extensive immunohistochemical testing ultimately diagnosed PM.
- The findings highlight the critical need to identify pseudomalignant conditions in order to prevent unnecessary aggressive treatments.
Ki-67 as a marker for differentiating borderline and benign phyllodes tumors of the breast: A meta-analysis and systematic review.
Ann Diagn Pathol
December 2024
Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, TX, USA.
Previously published studies raise the possibility of a link between breast phyllodes tumors (PT) grading and Ki-67 expression. In the current study, the authors conducted a literature review and meta-analysis to evaluate the association between the histological grades of PT and Ki-67 positivity, as well as the potential role of this immunomarker for the grading of PT. Observational studies grading PT and providing Ki-67 expression levels were retrieved from databases searches up to 11 August 2024, with 10 % or more of positive stromal cells being considered the cut-off point.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!